Summary:
- The FDA has approved Leqembi (lecanemab-irmb) for the treatment of early Alzheimer's disease.
- Leqembi is an intravenous (IV) maintenance dosing regimen that helps slow the progression of Alzheimer's symptoms in patients with early-stage disease.
- This approval marks a significant advancement in the treatment of Alzheimer's, as it provides a new option for patients to manage the debilitating effects of the disease.